Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • Searching Asian documents: patent search and monitoring services
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet and OPS
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Patent insight reports
    • Data
      • Overview
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge

    UP search

    Learn about the Unitary Patent in patent knowledge products and services

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Find a professional representative
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Unitary Patent

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • EPC Guidelines
      • PCT-EPO Guidelines
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National law relating to the UP
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives

    legal text

    Legal texts

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Firefighting technologies
      • Green tech in focus
      • CodeFest on Green Plastics
      • Clean energy technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    Listen to our podcast

  • Learning

    Learning

    The e-Academy – the point of access to your learning

    Go to overview 

    • Overview
    • European Patent Academy
      • Overview
      • Learning activities
      • Learning paths
    • Professional hub
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by area by profile
      • Overview
      • Business and IP managers
      • EQE candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)

    European Patent Academy

    Boost your IP knowledge with (e-)training from the European Patent Academy

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • A glimpse of the planned activities
      • Kids’ collaborative art competition
      • 50 Leading Tech Voices
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Governance
      • Overview
      • Communiqués
      • Calendar
      • Select Committee documents
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Public consultation on the EPO's Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Social responsibility
      • Overview
      • Environment and sustainability
      • Art collection
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s

    about us

    Patent Index 2022

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • Searching Asian documents
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
            • Go back
            • Overview
            • BG - Federated Register Service
            • GB - Federated Register Service
            • NL - Federated Register Service
            • MK - Federated Register Service
            • ES - Federated Register Service
            • GR - Federated Register Service
            • SK - Federated Register Service
            • FR - Federated Register Service
            • MT - Federated Register Service
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Patent insight reports
    • Data
      • Go back
      • Overview
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
          • Go back
          • EBD files (weekly download) - free of charge
            • Go back
            • Secure EBD ST.36 files (weekly download) - for national patent offices only
        • Boards of Appeal decisions
        • EP full-text data for text analytics
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Helpful resources
      • Go back
      • Overview
      • First time here? Patent information explained.
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Unitary Patent Guide
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Online Filing 2.0 pilot
        • MyEPO Portfolio - pilot phase
        • Online Filing 2.0 pilot continuation
        • Exchange data with us using an API
      • Get access
        • Go back
        • Overview
        • Installation and activation
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • EPC Guidelines
        • Go back
        • Overview
        • Archive
      • PCT-EPO Guidelines
        • Go back
        • Overview
        • Archive
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2023 ceremony
      • European Inventor Network
        • Go back
        • Activities granted in 2023
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • CodeFest on Green Plastics
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Patents and standards
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • European Patent Academy
      • Go back
      • Overview
      • Learning activities
      • Learning Paths
    • Professional hub
      • Go back
      • Overview
      • EPAC - European patent administration certification
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Archive
        • Candidates successful in the European qualifying examination
        • Compendium
          • Go back
          • Overview
          • Pre-examination
          • Paper A
          • Paper B
          • Paper C
          • Paper D
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
        • Go back
        • Overview
        • Patent enforcement in Europe
        • Patent litigation in Europe
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventors' handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
            • Go back
            • Overview
            • Is the idea ‘obvious’?
            • Prior art searching
            • Professional patent searching
            • Simple Espacenet searching
            • What is prior art?
            • Why is novelty important?
          • Competition and market potential
            • Go back
            • Overview
            • Research guidelines
          • Assessing the risk ahead
            • Go back
            • Overview
            • Exploitation routes
            • Significant commercial potential
            • Significant novelty
            • What about you?
            • What if your idea is not novel but does have commercial potential?
          • Proving the invention
            • Go back
            • Overview
            • Help with design or redesign
            • Prototype strategy
          • Protecting your idea
            • Go back
            • Overview
            • Forms of IPR
            • Patenting strategy
            • The patenting process
          • Building a team and seeking funding
            • Go back
            • Overview
            • Building a team
            • Sources of funding
            • Sources of help for invention
          • Business planning
            • Go back
            • Overview
            • Constructing a business plan
            • Keep it short!
          • Finding and approaching companies
            • Go back
            • Overview
            • First contact
            • Meetings
          • Dealing with companies
            • Go back
            • Overview
            • Advance or guaranteed payment
            • Companies and your prototype
            • Full agreement – and beyond
            • Negotiating a licensing agreement
            • Reaching agreement
            • Royalties
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • For IP professionals
          • For business decision-makers
          • For stakeholders of the innovation ecosystem
        • IP clinics
      • EQE Candidates
        • Go back
        • Overview
        • Coffee-break questions
        • Daily D questions
        • European qualifying examination - Guide for preparation
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Overview
      • 50 Leading Tech Voices
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Governance
      • Go back
      • Overview
      • Communiqués
        • Go back
        • Overview
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • Invoicing
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • Social responsibility
      • Go back
      • Overview
      • Environment
      • Art collection
        • Go back
        • Overview
        • The collection
        • Let's talk about art
        • Artists
        • Media library
        • What's on
        • Publications
        • Contact
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Procedure
    • Annual reports
      • Go back
      • Overview
    • Organisation
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
        • Composition of the Presidium
          • Go back
          • Overview
          • Archive
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2023
      • Archive
    • Annual list of cases
    • Communications
    • Publications
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
    • Case Law from the Contracting States to the EPC
    • Oral proceedings
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Legal resources
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
      • Specific contact
      • Surveys
        • Go back
        • Overview
        • Search services
        • Examination services, final actions and publication
        • Opposition services
        • Patent filings
          • Go back
          • Overview
          • Detailed methodology
          • Archive
        • Online Services
        • Patent information
          • Go back
          • Overview
          • Innovation process survey
        • Customer services
        • Filing services
        • Website
        • Survey on electronic invoicing
        • Companies innovating in clean and sustainable technologies
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Forums
    • Glossary
Board of Appeals
Decisions

Recent decisions

Overview
  • 2023 decisions
  • 2022 decisions
  • 2021 decisions
https://www.epo.org/en/node/t182160eu1
  1. Home
  2. T 2160/18 (Beta-glucosidase/ROAL OY) 20-10-2021
Facebook Twitter Linkedin Email

T 2160/18 (Beta-glucosidase/ROAL OY) 20-10-2021

European Case Law Identifier
ECLI:EP:BA:2021:T216018.20211020
Date of decision
20 October 2021
Case number
T 2160/18
Petition for review of
-
Application number
12151852.6
IPC class
C12N 9/42
C12N 15/56
C12P 19/02
C12P 7/06
C12N 1/14
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 557.56 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Treatment of cellulosic material and enzymes useful therein

Applicant name
Roal Oy
Opponent name
Novozymes A/S
Board
3.3.08
Headnote
-
Relevant legal provisions
European Patent Convention Art 54
European Patent Convention Art 56
European Patent Convention Art 76(1)
European Patent Convention Art 83
European Patent Convention Art 123(2)
Rules of procedure of the Boards of Appeal Art 12(4)
Keywords

Admittance of the new main request - (yes)

Added matter - (no)

Admittance of new evidence not admitted in opposition proceedings - (no)

Sufficiency of disclosure - (yes)

Admittance of new evidence filed in appeal proceedings - (no)

Novelty - (yes)

Inventive step - (yes)

Catchword
-
Cited decisions
T 0205/91
T 1002/92
T 0386/94
T 0737/00
T 1162/07
T 0971/11
T 0823/12
T 0942/12
Citing decisions
-

I. European patent No. 2 453 014 with the title "Treatment of cellulosic material and enzymes useful therein" was granted on the European patent application No. 12151852.6 which was filed as a divisional application of the earlier European patent application No. 06830936.8 published as WO 2007/071818 (in the following "the parent application"). In the present decision, references to "the application as filed" are to the original application documents.

II. The patent was opposed on the grounds for opposition under Article 100(a) in conjunction with Articles 54 and 56; 100(b) and 100(c) EPC.

III. In an interlocutory decision posted on 27 June 2018, an opposition division found that, while the subject-matter of claim 11 of the main request then on file extended beyond the content of the application as filed (Article 123(2) EPC), the claims and the invention according to the auxiliary request then on file met the requirements of the EPC. Document (15), which had been filed only three weeks before the oral proceedings, was not admitted into the proceedings.

IV. The opponent (appellant) filed an appeal and submitted a statement setting out the grounds of appeal including new evidence and copies of its written submissions in opposition proceedings including the documents cited therein.

V. By letter dated 20 May 2019, the patent proprietor (respondent) replied to the statement of grounds of appeal and submitted four sets of claims as new main request and auxiliary requests I to III in appeal proceedings, as well as additional evidence (Annexes IA to IC, IIA, IIB, III and IV).

VI. Claims 1, 2 and 9 of the main request read as follows:

"1. A polypeptide comprising a fragment having cellulolytic activity and being selected from the group consisting of:

a) a polypeptide comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 22; and

b) a fragment of a) having cellulolytic activity.

2. An isolated polynucleotide selected from the group consisting of:

a) a nucleotide sequence of SEQ ID NO: 21, or a sequence encoding a polypeptide of claim 1; and

b) a complementary strand of a).

9. The enzyme of[sic] preparation of claim 8, comprising a cellobiohydrolase comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 2, 4, 6 or 8, or to an enzymatically active fragment thereof, and a xylanase comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 18 or 20, or to an enzymatically active fragment thereof."

Independent claims 3, 4 and 5 are directed to, respectively, a vector, a host cell and an Escherichia coli strain. Independent claim 6 relates to an enzyme preparation comprising a polypeptide of claim 1, and dependent claims 7 and 8 are directed to embodiments of the enzyme preparation. Claims 10 to 12 relate to the use of the polypeptide of claim 1 or the enzyme preparation of claim 6. Independent claims 13 and 14 relate to, respectively, a method for preparing a polypeptide as defined in claim 1, and a method of treating cellulosic material. Claim 15 is directed to a further use of the polypeptide of claim 1.

VII. Pursuant to their request, the parties were summoned to oral proceedings before the board.

VIII. On 24 September 2021, the appellant withdrew its request for oral proceedings and informed the board that it would not attend the scheduled oral proceedings.

IX. In a communication sent in preparation for the oral proceedings, the board drew attention to matters which seemed to be of special significance and expressed a provisional opinion on some of the issues raised by the parties.

X. In reply to the board's communication, the respondent submitted four sets of claims as new auxiliary requests IV to VII.

XI. Oral proceedings were held on 20 October 2021 in the absence of the appellant. During the oral proceedings, the respondent filed amended pages 10 and 11 of the description.

XII. The following documents are referred to in this decision:

(2): J. Hong et al., 2007, Appl. Microbiol. Biotechnol., Vol. 73, pages 1331 to 1339;

(3): J. Hong et al., 2006, Appl. Microbiol. Biotechnol., Vol. 73, pages 80 to 88;

(4): N. J. Parry et al., 2001, Biochem. J., Vol. 353, pages 117 to 127;

(7): K. D. Speicher et al., author manuscript available in PMC, 5 August 2010, published in edited form as Curr. Protoc. Protein Sci., May 2001, pages 1 to 41;

(8): Declaration of Paul Vincent Harris, signed and dated 2 March 2017;

(11): C.C. Tong et al., 1980, Biochem. Jnl., Vol. 191, pages 83 to 94;

(12): E. R. de Palma-Fernandez et al., 2002, Folia Microbiol., Vol. 47, No. 6, pages 685 to 690;

(13): Experimental Report, dated 14 March 2018, unsigned;

(14): GENESEQP:AWH58322 Thermoascus aurantiacus beta-glucosidase;

(15): Experimental report - Isolation and Sequencing of Thermoascus aurantiacus IMI 216529 genomic DNA; unsigned and undated;

(16): Copy of email dated 25 April 2018;

(17): Declaration of Dr Mark Mogulis; signed and dated 5 November 2018; and

Annexes IA, IB, IC, IIA and IIB, dated 20 May 2019.

XIII. The submissions made by the appellant in writing, insofar as relevant to the present decision, were essentially as follows:

Article 83 EPC - sufficiency of disclosure

The requirements of Article 83 EPC were not met. Claim 1 specified a polypeptide having at least 80% identity to SEQ ID NO:22 which had cellulolytic activity. In view of the errors in the disclosed SEQ ID NO:22 (specifically, 19 amino acids deleted from the middle of the protein, and two frameshifts at the C-terminus of the protein), it was highly doubtful that the polypeptide actually had the purported activity. There was no evidence in the patent that polypeptides having the sequence of SEQ ID NO:22 - let alone sequence variants of up to 80% identity - had any cellulolytic activity (or, in fact, any enzymatic activity whatsoever). The legal burden of demonstrating that the claimed polypeptide had the claimed function was borne by the respondent.

Admittance of document (15) into the proceedings

The opposition division should have admitted document (15) into the proceedings. The document had been filed in direct response to issues raised by the opposition division in the summons; hence, it could not have been filed any sooner. The reasons given in the decision under appeal for disregarding document (15) were flawed. The document had been submitted more than three weeks ahead of the scheduled oral proceedings, admittedly after the Rule 116 EPC date. However, as shown in document (16) a copy had been sent concomitantly to the patent proprietor who could have studied the document closely and replied. Moreover, contrary to the opposition division's view document (15) was prima facie extremely relevant to novelty and inventive step because it confirmed by way of DNA sequencing that the beta-glucosidase described in document (4) fell within the scope of claims 1 and 2 of the patent.

Article 54 EPC - novelty

The opposition division had erred in its decision on novelty. Since claim 1 related to a product per se, the disclosure of the same beta-glucosidase in documents (4) and (11) destroyed the novelty of the claimed subject-matter, notwithstanding the fact that neither document explicitly reported the complete sequence of the identified beta-glucosidase. As shown by the evidence on file, a skilled person following the teaching of either document (4) or document (11) would isolate a beta-glucosidase as claimed.

Document (4)

The thermostable beta-glucosidase described in document (4) was the same beta-glucosidase claimed in claim 1. It had the same pH optimum and temperature optimum as the claimed beta-glucosidase. While the N-terminal sequence of the beta-glucosidase described in document (4) contained some amino acid differences compared to SEQ ID NO:22, it was clear from document (7) that this was likely to be due to high background from salts from the purification or the difficulties of accurate sequencing of prolines.

The opposition division's decision on novelty was based on the assumption that beta-glucosidase derived from different strains of the same microorganism were significantly different. This assumption was not supported by any documentary evidence, and it was disputed that this was "generally known" or even scientifically correct.

A difference in molecular weight between the beta-glucosidase of document (4) and that described in the patent was explainable on the basis of simple error and/or different levels of glycosylation. In any case, molecular weight was not a feature of the claims.

Even though document (4) only contained partial sequence information of the isolated beta-glucosidase, documents (2), (3), (8), (13) and (14) provided experimental evidence that the beta-glucosidase of document (4) must be the same as the beta-glucosidase of SEQ ID NO:22 or a slight variant thereof. As apparent from post-published documents (2) and (3), there were in fact only two beta-glucosidases produced by Thermoascus aurantiacus, only one of which was thermostable. Document (8) confirmed from the sequencing of the T. aurantiacus genome that - as a fact - the beta-glucosidase described in document (4) must be the same as the beta-glucosidase of SEQ ID NO:22 or a slight variant thereof. The skilled person repeating document (4) would therefore inevitably arrive at a polypeptide as claimed. Further evidence of the identity between the beta-glucosidase of document (4) and that of claim 1 was provided by documents (13) and (14).

The opposition division had adopted the wrong legal approach for using post-published documents and had failed to give appropriate consideration to the indirect evidence in documents (2), (3), (8), (13) and (14), which had led it to the wrong conclusions in relation to novelty.

Document (11)

The opposition division had made similar errors when deciding on novelty in light of document (11). It had failed to take proper account of the post-published evidence, and made the unsupported assertion that beta-glucosidases from different strains of Thermoascus would "differ significantly" and fall outside of the claim scope.

Article 56 EPC - inventive step

Document (4) as the closest state of the art

Document (4) was directed to the same problem as the alleged invention, namely providing a beta-glucosidase for the conversion of cellulose to soluble sugars that could be used at high temperatures. The solution of providing the thermostable beta-glucosidase from T. aurantiacus, as already isolated and characterized in document (4), was therefore completely obvious from that document. Since there was only one thermostable beta-glucosidase in T. aurantiacus, a person skilled in the art following the teachings of document (4) would inevitably arrive at a polypeptide falling within the scope of claim 1. As there was no disclosure of specific fragments of the polypeptide in the application, any true fragments would have to be obvious in order for them to be sufficiently disclosed.

Contrary to the opposition division's view, the claimed beta-glucosidase was not actually "vastly different" to the one identified in document (4). Any differences that might exist would not be so surprising to the skilled person to allow inventive step to be recognised. The skilled person would not place particular significance on a difference in molecular weight. Being aware of the potential for error in the sequence information in document (4), the skilled person would not be surprised to obtain an alternative beta-glucosidase with a slightly different N-terminal sequence. Accordingly, the opposition division had erred by attributing inventive step to "surprising" features of the claimed beta-glucosidase that did not exist. The opposition division regarded the claimed beta-glucosidase as inventive on the basis of its "improved temperature stability". However, claim 1 encompassed a range of beta-glucosidases which could have very different stabilities. There were no comparative data showing an improvement of the claimed beta-glucosidase over the one in document (4).

Document (12) as the closest state of the art

Document (12) reported the presence of multiple beta-glucosidase in T. aurantiacus and provided the skilled person with an incentive to look for other beta-glucosidases. The objective technical problem would be finding an alternative beta-glucosidase in T. aurantiacus. In view of decisions T 823/12 of 23 August 2016 and T 386/94 of 11 January 1996, neither the isolation of another beta-glucosidase from T. aurantiacus, nor its cloning and expression using standard methods could be considered to involve an inventive step over document (12).

XIV. The submissions made by the respondent, insofar as relevant to the present decision, may be summarized as follows:

Admittance of the main request into the proceedings

Since both in the preliminary opinion and the interlocutory decision under appeal the opposition division had regarded the requirements of Articles 83, 54 and 56 EPC as met, there had been no need to present amended claims in opposition proceedings. The main request filed in appeal proceedings was a direct reaction on the appellant's substantiation of the grounds of appeal. Hence, the request was to be admitted.

Article 83 EPC - sufficiency of disclosure

The objection of lack of sufficient disclosure was exclusively based on speculation and by no means complied with the legal requirement of serious doubts substantiated by verifiable facts. The fact that the amino acid sequence of SEQ ID NO:22 contained some errors was not prejudicial, because at the priority date the skilled person could have obtained a beta-glucosidase as claimed by expressing the beta-glucosidase gene included in a plasmid obtainable from the deposited Escherichia coli DSM16725.

The appellant had not provided any evidence to support its allegation that neither a polypeptide having the amino acid sequence of SEQ ID NO:22 nor a polypeptide encoded by the nucleotide sequence of SEQ ID NO:21 had beta-glucosidase activity. In contrast, the experimental evidence provided in Annexes IIA and IIB showed that those polypeptides had beta-glucosidase activity and a pH optimum of 4.5.

Admittance of document (15)

The opposition division had exercised correctly its discretion not to admit document (15) into the proceedings. Already when filing the opposition brief, the appellant should have backed up its allegation of lack of novelty over document (4) by means of experimental evidence. The appellant itself admitted that document (15) was not more relevant than document (13) already on file. In line with Article 12(4) RPBA 2007, document (15) was not to be admitted into the appeal proceedings.

Article 54 EPC - novelty

The subject-matter of claim 1 was novel over document (4). The appellant had not proved beyond doubt that the polypeptide isolated in document (4) was the same as that defined in claim 1. The same applied as regards document (11).

Article 56 EPC - inventive step

Starting from document (4), the objective problem to be solved was the provision of a further thermostable beta-glucosidase for use in methods of treating cellulosic biomass, e.g. for the production of biofuel. Four different documents on file (documents (1), (4) (11) and (12)) described thermostable beta-glucosidases of T. aurantiacus which were characterized by different molecular weights ranging from 85 to 175 kD. As shown in document (8), sequencing of the T. aurantiacus genome carried out after the relevant date had revealed eight predicted members of the Glycosyl Hydrolase family 3 (GH3).

A person skilled in the art could not have isolated a polypeptide having SEQ ID NO:22 on the basis of the information given in document (4). PCR would not have been feasible because the amino acid sequence described in document (4) would have allowed to design only a single primer. In view of the fact that several GH3 beta-glucosidase polypeptides with the same conserved regions were present in T. aurantiacus, it had not been obvious to a skilled person to arrive at the polypeptide of claim 1.

XV. The appellant requested in writing that the decision under appeal be set aside and that the patent be revoked.

XVI. The respondent requested that the patent be maintained on the basis of the claims of the main request or any of the auxiliary requests I to III, all filed on 20 May 2019, or on the basis of any of the auxiliary requests IV to VII filed on 1 October 2021.

Admittance of the main request into the proceedings

1. In the decision under appeal, the auxiliary request then on file was considered to fulfil the requirements of the EPC. The set of claims of the present main request, which was filed together with the respondent's reply to the statement of grounds of appeal, differs from the auxiliary request underlying the decision under appeal in that claim 2 has been deleted, and claim 10 (re-numbered as claim 9) has been amended to (i) omit from the enzyme preparation the endoglucanase defined by reference to SEQ ID NOs:10, 12, 14 and 16, and an enzymatically active fragment thereof; and (ii) require the presence of a previously optional xylanase.

2. The appellant did not oppose the admittance of the amended claims into the proceedings. As the amendments introduced into the claims were made in response to specific objections under Article 123(2) EPC raised in the statement of grounds of appeal, the board decided to admit and consider the present main request.

Rule 80 and Articles 123(2)(3), 76(1) and 84 EPC

3. The amendments introduced into the claims are occasioned by the ground for opposition of Article 100(c) EPC. Hence, the requirement of Rule 80 EPC is met.

4. In the decision under appeal, the opposition division found that the subject-matter of the claims according to the auxiliary request then on file did not extend beyond the content of either the parent application or the application as filed (see points 3.c) and d) on page 4 of the decision). The appellant contested this finding only with regard to claims 2 and 10.

5. In the present main request, claim 2 has been deleted, and claim 10 amended and re-numbered as claim 9. The appellant did not dispute that the subject-matter of amended claim 9 is disclosed in the parent application and the application as filed. As the board has no doubt that the claimed subject-matter is directly and unambiguously derivable from claims 18, 26 and 28 of the parent application; and page 6, lines 14 to 17; page 18, lines 33 to 36; and page 16, lines 3 to 5 of the application as filed, the amendments introduced into the claim are considered to conform both Article 123(2) and Article 76(1) EPC.

6. No objections were raised by the appellant with regard to Article 123(3) EPC or Article 84 EPC. The board sees no reason to raise any of its own motion.

Article 83 EPC - sufficiency of disclosure

7. In the decision under appeal, the opposition division found that the objection of lack of sufficient disclosure had not been substantiated by verifiable facts, and considered the invention as defined in claim 1 of the auxiliary request to be sufficiently disclosed in the application as filed.

8. In its statement of grounds of appeal, the appellant disagreed with the opposition division's legal reasoning and contested the findings on Article 83 EPC arguing - for the first time - that there was no evidence that "... the (incorrectly deduced) polypeptide sequence of SEQ ID NO:22 has cellulolytic activity, as the claims required". In appellant's view, the respondent "... bears the legal burden of demonstrating that the claimed polypeptide has the claimed function" (see sections 10.3 and 10.8 of the statement of grounds of appeal).

9. Annexes IA to IC, IIA and IIB were submitted by the respondent together with its reply to the statement of grounds of appeal in order to address appellant's argument. The board is satisfied that there had been no reason for the respondent to present this evidence in opposition proceedings. This has not been disputed by the appellant. Hence, having been presented in due time, Annexes IA to IC, IIA and IIB are taken into account by the board for its decision.

10. It is undisputed that the polypeptide sequence of SEQ ID NO:22 of the application as filed contains errors. Annex IA shows the nucleotide sequence and the polypeptide sequence disclosed in the application as filed as, respectively, SEQ ID NO:21 and SEQ ID NO:22; introns and CDSs are indicated. It also shows the errors in these sequences arising from an erroneous intron annotation (see page 5) and three additional nucleotides that in fact do not exist (see nucleotides C3264, T3291 and A3297 on page 6). The corrected sequence is provided for comparison. In Annex IB, the polypeptide sequence of SEQ ID NO:22 is compared to the sequence encoded by SEQ ID NO:21 disclosed in the application as filed and to the correct polypeptide sequence. Annex IC shows the comparison between the polypeptide sequence of SEQ ID NO:22 and the correct polypeptide sequence.

11. The experimental evidence in Annexes IIA and IIB shows that polypeptides produced by expressing either (i) a synthetic gene encoding the polypeptide of SEQ ID NO:22 (Annex IIA) or (ii) the nucleotide sequence of SEQ ID NO:21 (Annex IIB) inserted into an expression cassette for T. reesei, have in fact beta-glucosidase activity. As apparent from Figure 2 of each Annex IIA and IIB, the pH optimum of both beta-glucosidase enzymes is about pH 4.5.

12. This experimental evidence was not questioned by the appellant, and the board is satisfied that the burden of proving that a polypeptide having the sequence of SEQ ID NO:22 has cellulolytic activity, has been discharged.

13. As regards appellant's argument concerning the beta-glucosidase activity of variants of the polypeptide encoded by SEQ ID NO:22, the experimental results reported in Annex IIB show that the polypeptide encoded by SEQ ID NO:21, which differs from the polypeptide of SEQ ID NO:22 by 20 amino acids, i.e. is 97% identical (see Annex IB), has cellulolytic activity. The board has no doubts that a person skilled in the art at the relevant date was able to find further polypeptides having cellulolytic activity and at least 80% identity to SEQ ID NO:22, without undue burden or inventive skills.

14. Hence, having considered the arguments and evidence put forward by the parties in appeal proceedings, the board concludes that the patent application discloses the claimed invention in a manner sufficiently clear and complete for it to be carried out by the person skilled in the art. Thus, the requirements of Article 83 EPC are fulfilled.

Admittance of document (15)

15. Document (15) was filed by the present appellant three weeks before the date of the oral proceedings before the opposition division. The document purportedly confirms by way of DNA sequencing that the beta-glucosidase from T. aurantiacus described in document (4) falls within the scope of claims 1 and 2 of the patent as granted and, consequently, deprives the subject-matter of these claims of novelty (see submission of the present appellant - then opponent - dated 25 April 2018).

16. In the decision under appeal, the opposition division decided not to admit document (15) into the proceedings, on the grounds that the document had been filed late and not sent to the other party until an even later date, and that, prima facie, the experimental evidence therein did not appear to be relevant (see first full paragraph on page 5 of the decision under appeal). The appellant has contested these findings.

17. According to established case law of the Boards of Appeal, evidence first submitted by an opponent after expiry of the nine-month period under Article 99(1) EPC is generally to be regarded as not filed in due time for the purpose of Article 114(2) EPC and the opposition division has in principle discretion not to admit it. In the present case, the objection of lack of novelty in view of document (4) had been raised already in the notice of opposition. Hence, the evidence in document (15) could - and should - have been submitted within the time limit for filing an opposition pursuant to Article 99(1) EPC.

18. Even if the board were to accept appellant's argument that document (15) had been submitted in response to an observation made by the opposition division in the communication attached to the summons to oral proceedings, the document should nevertheless have been submitted, at the latest, at the date fixed by the opposition division for making written submissions in preparation for the oral proceedings under Rule 116(1) EPC, i.e. two months before the date of the oral proceedings (see last sentence on page 8 of the opposition division's communication dated 17 November 2017). Since the document was submitted only three weeks before the date of the oral proceedings, there is no doubt that document (15) was not filed in due time, and that its admission into the opposition proceedings was at the discretion of the opposition division (see Article 114(2) EPC).

19. The decision of the opposition division to disregard the late-filed document (15) could be overruled only if the board were to conclude that the opposition division exercised its discretion according to wrong principles, or without taking into account the right principles, or in an unreasonable way (see decision G 7/93, OJ EPO 1994, 775, point 2.6 of the Reasons). This is however not the case.

20. According to established jurisprudence of the Boards of Appeal, a decisive criterion to be taken into account by the opposition division when deciding on the admissibility of late-filed documents, is their prima facie relevance (see, e.g., decision T 1002/92, OJ EPO 1995, 605). As apparent from the decision under appeal, the opposition division took into account this issue and concluded that document (15) was prima facie not sufficiently relevant to change the outcome of the opposition proceedings (see section 5.c on page 5 of the decision under appeal).

21. The opposition division considered also the question whether the patent proprietor had been in a position to adequately react to the submission of document (15). In this context, the opposition division stated in its decision that document (15) had not been forwarded to the patent proprietor "until an even later date", i.e. even less than three weeks before the oral proceedings. The appellant contested this finding and submitted document (16) as evidence that document (15) had been sent via email to the other party on the same date as to the opposition division, i.e. three weeks before the oral proceedings.

22. However, document (16) filed in appeal proceedings does not call into question the exercise of discretion by the opposition division which was based on the evidence then on file. As apparent from the minutes of the oral proceedings before the opposition division, dated 27 June 2018 (see last paragraph on page 1), the patent proprietor declared that no email from the opponent had been received. In the absence of evidence on file that an email including document (15) had been sent to and received by the patent proprietor, the opposition division correctly found that document (15) became available to the patent proprietor only at a later date, i.e. when it was forwarded by the division few days before the oral proceedings.

23. In view of the above, the board is satisfied that the opposition division exercised its discretion correctly and in a reasonable way, and sees no reason to overturn the opposition division's discretionary decision not to admit document (15) into the opposition proceedings in accordance with Article 114(2) EPC.

24. Nor does the board see any reason to exercise its own discretion under Article 12(4) RPBA 2007 to admit into the appeal proceedings either document (15) or appellant's submissions relying on this document, even giving due consideration to the evidence provided in document (16) (see decisions T 971/11 of 4 March 2016, point 1 of the Reasons; and T 942/12 of 17 November 2015, point 7 of the Reasons).

25. Like the opposition division, the board holds the view that document (15) is prima facie not sufficiently relevant to change the outcome of the proceedings. The experimental evidence in document (15) might show that a nucleotide sequence encoding a polypeptide having an amino acid sequence which is at least 80% identical to SEQ ID NO:22 is present in the genome of T. aurantiacus IMI 216529. However, contrary to appellant's view document (15) does not serve to prove beyond doubt that the method described in document (4) inevitably leads to such a polypeptide.

26. Hence, document (15) was not admitted into the appeal proceedings.

Admittance of document (17)

27. Document (17), which was filed together with the statement of grounds of appeal, is a declaration of Dr Mark Wogulis, an employee of the appellant. In sections 11 to 14 of this document, Dr Wogulis makes some statements on the question whether or not it is generally thought that significant variability in the amino acid sequence of a given protein exists among different strains of a fungal species. Since this issue was brought forward by the examining division in its communication in preparation for the oral proceedings (see second and third sentence in section 3.c on page 4), the board fails to see any reason why this evidence could not have been submitted in opposition proceedings.

28. It is not clear which objection (lack of novelty or lack of inventive step) Dr Wogulis' statements in sections 5 to 10 of his declaration are intended to support. In any case, both objections were raised in the notice of opposition, and in the opposition division's communication in preparation for the oral proceedings, which was issued six months in advance of the oral proceedings, a provisional view adverse to the present appellant was expressed. Hence, the declaration of Dr Wogulis could and should have been submitted already in opposition proceedings.

29. For these reasons, the board holds the evidence in document (17) not to be inadmissible.

Article 54 EPC - novelty

30. Claim 1 of the present main request is identical to the corresponding claim of the auxiliary request underlying the decision under appeal. The opposition division regarded the subject-matter of claim 1 of the auxiliary request then on file as novel in the light of the content of documents (4) and (11). This applied also to the remaining claims which referred to claim 1 (see section 5c bridging pages 7 and 8 of the decision).

Document (4)

31. It is established jurisprudence of the Boards of Appeal that, for concluding lack of novelty, the claimed subject-matter must be directly and unambiguously derivable from the prior art. For ascertaining the disclosure of a document forming part of the state of the art within the meaning of Article 54(2) EPC, the relevant date is the date of its publication (see T 205/91 of 16 June 1992, T 737/00 of 21 May 2003, and T 1162/07 of 6 October 2010). It has to be beyond doubt - not merely probable - that the disclosure in the state of the art would inevitably lead to subject-matter falling within the scope of the claim.

32. Document (4) describes the purification and biochemical characterization of an extracellular thermostable beta-glucosidase from Thermoascus aurantiacus IMI 216529. The beta-glucosidase was purified to homogeneity by DEAE-Sepharose, Ultrogel AcA 44 and mono-P column chromatography (see Abstract and paragraph bridging pages 119 and 120). The enzyme is said to be a homotrimer, with a monomer molecular mass of 120 kDa, the trimer being optimally active at 80°C and at pH 4.5 (see Abstract and page 120, left-hand column). In Figure 8, an N-terminal sequence of 20 amino acid residues of the beta-glucosidase is described. Based on the high degree of N-terminal sequence identity with other beta-glucosidases, the authors of document (4) suggest that the enzyme could be a member of glycoside hydrolase family 3 (see Abstract and page 126, right-hand column, second sentence of the last paragraph).

33. It is undisputed that document (4) does not explicitly report the complete sequence of the isolated beta-glucosidase, and that only 11 amino acid residues out of the N-terminal sequence of 20 amino acid residues described in document (4) are identical to a sequence in SEQ ID NO:22 of the present patent, whereas the amino acids at positions 1 and 13 to 20 differ between the two sequences. Hence, like the opposition division, the board holds that the sequence data provided in document (4) do not allow to establish without doubt the identity between the beta-glucosidase described therein and that defined in claim 1.

34. Relying on document (7), the appellant argued that the differences between the sequence provided in document (4) and that of SEQ ID NO:22 were clearly due to inaccuracies in the sequencing technique used in document (4). However, for the purpose of examining novelty, document (4) is to be assessed from the perspective of a person skilled in the art at the publication date. The skilled person does not find in document (4) any indication whatsoever of possible errors in the amino acid sequence provided therein, let alone which partial sequence might be erroneous. Thus, there was no reason for the skilled person at the publication date of document (4) to suspect that the amino acid sequence provided therein contained any errors.

35. For its finding on novelty, the opposition division took into account also differences between the beta-glucosidase polypeptide described in document (4) and that of the invention as regards the molecular weight (120 kDa vs. 81 kD) and the optimal temperature (80°C vs. 75°C). The appellant tried to explain the striking difference in molecular weight on the basis of simple error and/or different levels of glycosylation. However, a person skilled in the art cannot derive from document (4) any indication for a potential error when determining the molecular weight of the beta-glucosidase polypeptide described therein. Nor is there any mention in document (4) of a possible glycosylation of the polypeptide.

36. Further, the appellant relied on post-published documents (2) and (3) to support its contention that T. aurantiacus produces only two beta-glucosidases, of which only one is thermostable. In appellant's view, the thermostable beta-glucosidase polypeptides described in documents (4) and (2) must be the same as the beta-glucosidase polypeptide of the invention.

37. This argument is not persuasive. Document (12), on which the appellant relied for inventive step, describes three beta-glucosidases in T. aurantiacus (see Figure 1), and characterises two of them (Gl-2 and Gl-3) as being thermostable and having different pH and temperature optima. Moreover, it is apparent from document (8) that, based on the post-published sequence of the genome of T. aurantiacus, up to eight putative beta-glucosidases may be produced in this organism.

38. In the board's view, document (2) - and document (8) - may show that a nucleotide sequence encoding a polypeptide having an amino acid sequence which is at least 80% identical to SEQ ID NO:22 is present in the genome of T. aurantiacus. However, these documents do not prove beyond doubt that carrying out the method described in document (4) inevitably leads to a polypeptide with beta-glucosidase activity and having an amino acid sequence at least 80% identical to SEQ ID NO:22.

39. Similarly, the experimental evidence in documents (13) and (14) may show that a polypeptide having beta-glucosidase activity and sharing several partial amino acid sequences with SEQ ID NO:22 of the patent is present in T. aurantiacus IMI 216529, which is the same strain used in document (4). However, in view of the fact that T. aurantiacus appears to produce several beta-glucosidases (see document (12)), and that the method used in document (13) for isolating the beta-glucosidase polypeptide from which the partial amino acid sequences are obtained, differs substantially from the method used in document (4), documents (13) and (14) cannot be considered to prove beyond doubt that carrying out the method described in document (4) inevitably leads to a polypeptide having beta-glucosidase activity and an amino acid sequence which is at least 80% identical to SEQ ID NO:22.

40. For these reasons, novelty over document (4) is acknowledged.

Document (11)

41. Document (11) describes a thermostable beta-glucosidase with a molecular weight of 87 kDa which is optimally active at pH 4.5-5.0. However, document (11) does not provide any amino acid sequence and there is no proof that carrying out the method described in this document inevitably leads to a beta-glucosidase falling within the scope of claim 1. As stated above, it is apparent from document (12) that T. aurantiacus produces at least two thermostable beta-glucosidases. It is stated in this document that the method described in document (11) for the purification of the thermostable beta-glucosidase "... was not efficient in separating the [two] enzymes", and that ion-exchange chromatography was crucial (see document (12), page 688, lines 1 to 5, and the reference to Tong et al. (1980) which is document (11) in the present proceedings). Since the method described in document (11) does not involve ion-exchange chromatography for the purification of the beta-glucosidase, it is uncertain which enzyme(s) result(s) from carrying out the described method. Thus, a polypeptide as defined in claim 1 cannot be considered to be directly and unambiguously derivable from document (11).

42. Consequently, also novelty over document (11) is acknowledged.

Article 56 EPC - inventive step

Document (4) as the closest state of the art

43. It is common ground that, starting from document (4) as the closest state of the art, the technical problem to be solved is the provision of an alternative thermostable beta-glucosidase from T. aurantiacus. Hence, for assessing inventive step the question whether or not the claimed polypeptide shows any advantageous properties compared to the polypeptide described in document (4) does not need to be considered, contrary to appellant's view.

44. In view of the experimental evidence in the examples of the patent and Annexes IIA and IIB, there is no doubt that the problem is solved by a polypeptide as defined in claim 1.

45. Having considered the arguments put forward by the appellant, the board is not persuaded that a person skilled in the art relying on the information given in document (4) would have arrived at a polypeptide as claimed in an obvious manner.

46. The appellant argued that providing the same beta-glucosidase already isolated and characterized in document (4) was obvious. However, as discussed in the context of novelty above, the appellant failed to provide convincing evidence that the polypeptide isolated in document (4) was in fact the same as the polypeptide of SEQ ID NO:22, or that a person skilled in the art applying the method described in document (4) would have isolated a polypeptide as defined in claim 1. As document (4) teaches a beta-glucosidase polypeptide with a molecular weight of 120 kD, it was in fact obvious to the skilled person to try to isolate such a polypeptide. However, document (4) does not teach or suggest that T. aurantiacus may produce other beta-glucosidases, and without knowledge of the present invention, the skilled person would not have expected to isolate a further beta-glucosidase polypeptide with a substantially lower molecular weight, let alone the specific polypeptide defined in claim 1. The appellant failed to substantiate convincingly its allegation that the skilled person would not place particular significance on the molecular weight reported in document (4).

47. Also appellant's argument that the skilled person could have used the sequence information provided in document (4) to clone a nucleic acid encoding the described polypeptide, is unconvincing. The board shares the respondent's view that the amino acid sequence described in document (4) would not be sufficient to allow the skilled person to design PCR primers. As regards hybridization with a degenerated probe designed on the basis of the amino acid sequence described in document (4), in view of the substantial differences between that sequence and the sequence of SEQ ID NO:22 (see paragraph 33 above) it is highly doubtful whether the skilled person would be able to isolate, without undue burden, a nucleotide sequence encoding the claimed polypeptide.

48. For these reasons, the subject-matter of claim 1 cannot be regarded as obvious in view of the teachings of document (4).

Document (12) as the closest state of the art

49. Document (12) describes the partial purification and characterization of two thermostable beta-glucosidases (GI-2 and GI-3) from T. aurantiacus having a molecular weight of 175 kD and 157 kD, respectively (see Abstract). There is no evidence on file that the thermostable GI-2 and GI-3 beta-glucosidase polypeptides characterized in document (12) may have any similarity to the polypeptides of the invention. The fact that their molecular weight differs substantially from the molecular weight of the polypeptide isolated by the present inventors appears to indicate that they are in fact different polypeptides. Document (12) does not provide any sequence information for the characterized beta-glucosidases.

50. Starting from document (12), the technical problem to be solved is the provision of an alternative thermostable beta-glucosidase from T. aurantiacus. The solution is a polypeptide as defined in claim 1.

51. Since document (12) described at least two beta-glucosidase polypeptides in T. aurantiacus, the skilled person could have attempted to isolate a further polypeptide applying the purification method described in document (12), as it is apparent from Figure 1 of this document that a third fraction (GI-1) having beta-glucosidase activity was eluted from the anion-exchanger column. There is however no evidence on file showing that the third fraction described in document (12) contained a polypeptide as defined in claim 1, and the appellant did not argue to this effect.

52. The appellant did not put forward any arguments as to which obvious course of action would have been taken by the skilled person, starting from document (12), to arrive at the claimed beta-glucosidase polypeptides in an straightforward manner. Rather, the appellant substantiated its objection of lack of inventive step basically by referring to decision T 823/12 of 23 August 2016 and decision T 386/94 of 11 January 1996. The facts underlying the cited decisions differ however from the facts in the present case.

53. In decision T 823/12 (supra), which relates to polypeptides having cellulolytic enhancing activity produced by the filamentous fungus Thielavia terrestris, the document considered to be the closest state of the art ("D1") described the identification and cloning of five genes encoding such polypeptides, by applying an experimental procedure which involved the use of EST sequences to identify sequences encoding the desired polypeptides. In the application then at issue, the same experimental procedure was applied for identifying and cloning a further gene coding for a polypeptide having cellulolytic enhancing activity from the same fungus. The board found that the fact that the closest state of the art "... had already disclosed that 13 genes from the assembled EST sequences had hits against known glycosyl hydrolase genes [...] justified the reasonable expectation that there were more glycosyl hydrolase genes in Thielavia terrestris than the five which were cloned in D1" (see point 2.5 of the Reasons). Thus, the board concluded that the claimed polypeptides did not involve an inventive step.

54. In the present case, document (12) describes the isolation and characterization of two beta-glucosidase polypeptides from T. aurantiacus, but does not suggest, let alone expressly indicates that T. aurantiacus may produce further thermostable beta-glucosidases. Nor does document (12) provide any sequence data on the basis of which the skilled person could have identified genes encoding further beta-glucosidase polypeptides. Instead of the purification method described in document (12), the present invention uses a different approach to isolate the beta-glucosidase polypeptide with the degree of purity required for peptide sequencing. While this may appear trivial, given the large amount of different polypeptides secreted by cellulolytic fungi it is not. In view of these factual differences, the board does not deem the conclusion of lack of inventive step in decision T 823/12 (supra) applicable to the present case.

55. To support its allegation that the cloning and expression of the claimed beta-glucosidase using standard methods could not be inventive, the appellant cited the Headnote of decision T 386/94 (supra). However, the factual situation underlying the cited decision cannot be compared to that in the present case. Decision T 386/94 (supra) relates to a process for producing chymosin polypeptide or its precursors which involves the cloning and expression of a DNA sequence encoding the polypeptides. The document representing the closest state of the art described the chymosin polypeptide and its precursor prochymosin, as well as the isolation of a recombinant clone containing sufficient cDNA to code for 80% of the prochymosin polypeptide (se point 25 of the Reasons). The competent board found that a person skilled in the art would have perceived the cloning and expression of the chymosin DNA "... as an endeavour likely to succeed and that achieving this cloning did not pose such problems as to prove that this assumption was wrong". Consequently, the board concluded that the claimed process did not involve an inventive step (see point 42 of the Reasons).

56. In decision T 386/94 (supra), chymosin and its precursors were well-characterised polypeptides, their amino acid sequence was known and a DNA molecule encoding 80% of the precursor prochymosin had been isolated, the actual achievement of the claimed invention being the cloning and expression of the complete DNA sequence. In contrast, in the present case it was uncertain at the relevant date whether T. aurantiacus produced further beta-glucosidase polypeptides, further polypeptides had not been characterized, their amino acid sequence was unknown and a DNA sequence encoding them had not been identified. As these facts differ substantially from those in decision T 386/94 (supra), the board's conclusion in that decision cannot apply to the present case.

57. Summarising the above: the arguments put forward by the opponent to substantiate its objection of lack of inventive step over document (12) fail to persuade the board.

Adaptation of the description

58. At the oral proceedings before the board, the respondent submitted amended pages 10 and 11 of the patent to adapt the description to the amended claim 9.

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the opposition division with the order to maintain the patent on the basis of claims 1 to 15 of the main request filed on 20 May 2019 and a description consisting of description, sequence listing and figures of the patent as granted, except for pages 10 and 11 of the description to be replaced by amended pages 10 and 11 as filed at the oral proceedings before the board.

Footer - Service & support
  • Service & support
    • FAQ
    • Contact us
    • Subscription centre
    • Official holidays
    • Publications
    • Procedural communications
    • Ordering
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
SoMe facebook 0
European Patent Office
EPO Jobs
SoMe instagram
EuropeanPatentOffice
SoMe linkedIn
European Patent Office
EPO Jobs
EPO Procurement
SoMe twitter
EPOorg
EPOjobs
SoMe youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility